Clinical evaluation of Cefsulodin (SCE-129, CFS), a new antipseudomonal cephalosporin, was made and the following results were obtained.
1) CFS was given to 13 patients with chronic, complicated urinary tract infections due to Pseudomonas aeruginosa by mainly intramuscular dose of 600-1, 000mg per day.
Good therapeutic effects were obtained in 6 patients out of 13 or 46.2%.
2) No adverse effect was seen except abnormal changes in laboratory findings in 3 pateints. One is a slight elevation of GOT or GPT in 2 patients and these laboratory findings became normal after discontinuation of the treatment. The other abnormal changes were elevation of BUN and s-Cr in one patient. It is impossible to claim that the abnormal changes in renal function were completely induced by CFS because of pre. and posttreatment of the other antibiotics. The abnormality return to normal by taking two weeks, so CFS should be given with cation to patients with potential renal insufficiency.
3) CFS is an unique cephalosporin antibiotic which shows good therapeutic effet, similar to aminoglycosides or antipseudomonal penicillins, against Pseudomonas aeruginosa infections.
